Targovax ASA
OSE:TRVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hino Motors Ltd
OTC:HINOF
|
JP |
|
Sphere 3D Corp
F:8S3
|
CA |
|
T
|
Tasty Fries Inc
OTC:TFRY
|
US |
|
U
|
United Laboratories International Holdings Ltd
F:UNJ
|
HK |
Targovax ASA
Research & Development
Targovax ASA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Targovax ASA
OSE:TRVX
|
Research & Development
-kr77.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Research & Development
-kr72.6m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Research & Development
-kr25.9m
|
CAGR 3-Years
29%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-10%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Research & Development
-kr2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Targovax ASA
Glance View
Targovax ASA is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company is headquartered in Lysaker, Akershus and currently employs 22 full-time employees. The company went IPO on 2014-06-16. The firm is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The firm's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The firm's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The firm's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.
See Also
What is Targovax ASA's Research & Development?
Research & Development
-77.6m
NOK
Based on the financial report for Dec 31, 2022, Targovax ASA's Research & Development amounts to -77.6m NOK.
What is Targovax ASA's Research & Development growth rate?
Research & Development CAGR 1Y
-23%
Over the last year, the Research & Development growth was -23%.
